




The relative strengths and weaknesses of Epirus Biopharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Epirus Biopharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 66% points. The greatest weakness of Epirus Biopharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 242%, being 22% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	38,369
Cost of Goods Sold	0
Intangible Assets	17,654
Liabilities, Current	19,631
Liabilities, Non-Current	0
Other Assets	1,817
Other Compr. Net Income	18
Other Expenses	6,718
Other Liabilities	0
Other Net Income	241
Other Revenues	12,550
Property and Equipment	3,535
Research and Development	41,423
Selling, General and Administrative Expense	8,977

Output Variable	Value in 1000 USD
Assets	61,375
Liabilities	19,631
Expenses	57,118
Revenues	12,550
Stockholders Equity	41,744
Net Income	-44,327
Comprehensive Net Income	-44,318
BaseVar	75,466
ECR before LimitedLiability	115%
Economic Capital Ratio	242%